Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 13, 2011

Aslan Pharmaceuticals Licenses Array’s Phase II-Stage Solid Tumor Candidate

Aslan Pharmaceuticals Licenses Array’s Phase II-Stage Solid Tumor Candidate

Array will initiate proof-of-concept program in Asia for ARRY-543 against gastric cancer.[© picsfive - Fotolia.com]

  • Aslan Pharmaceuticals negotiated a license to Array BioPharma’s Phase II-ready Her2/EGFR inhibitor, ARRY-543. Under terms of the deal Aslan will fund and globally develop the anticancer candidate through proof-of-concept, initially targeting patients with gastric cancer. The initial program will be carried out in Asia.

    On achieving Phase II success Aslan will then identify a global partner for late-stage development and commercialization. Array says that it will be eligible to receive a significant portion of the proceeds from a partnering transaction signed by Aslan. The overall deal between Array and Aslan includes an option to work together on a second compound.

    “Our partnership with Aslan provides a great opportunity to fund and advance the development of ARRY-543," comments Robert E. Conway, Array’s CEO. “Aslan’s creative development strategy of leveraging Asia to conduct clinical development is particularly compelling for ARRY-543 due to the high prevalence of patients with gastric cancer in Asia.”

    The outlicensing deal for ARRY-543 comes just a month after Array announced a cash-saving restructuring plan that will see the firm cut its workforce by 20%, primarily in discovery research and support. The smaller, fully integrated R&D capacity will focus on advancing ongoing partnered programs with Amgen, Celgene, and Genentech, and a number of  late-stage discovery programs.

    The firm said it would in addition push forward with three key Phase I and II in-house programs: ARRY-520 is a KSP inhibitor in development primarily against myeloma, ARRY-614 is a p38/Tie-2 inhibitor for the treatment of myelodysplastic syndrome, and MEK162 is a MEK inhibitor anticancer agent in development in partnership with Novartis.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »